Eyenovia Expands Scientific Advisory Board With Addition of Two Leaders in Optometry

By
More Images
NEW YORK—Eyenovia Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company, has announced that professor Mark Bullimore, PhD, and April Jasper, OD, have joined Eyenovia’s scientific advisory board. Bullimore is an internationally renowned scientist, speaker, and educator, and Jasper has extensive experience in various modes of optometric practice, according to the announcement. “We are very pleased to welcome two highly accomplished and respected optometrists to our scientific advisory board,” Dr. Sean Ianchulev, Eyenovia’s chief executive officer and chief medical officer, said in the announcement.

He added, “We believe professor Mark Bullimore and Dr. April Jasper will bring a wealth of scientific, academic and practical experience in optometry and more specifically in childhood myopia and presbyopia to our company. We look forward to leveraging their experience as we continue enrolling patients in our Phase III 'Chaperone' study for progressive myopia and prepare to initiate our Phase III 'Vision' studies for presbyopia in 2020.”

Bullimore is currently an adjunct professor at the University of Houston College of Optometry and is also the associate editor of Ophthalmic and Physiological Optics. He is a Fellow of the American Academy of Optometry and a Gold Fellow of the Association for Research in Vision and Ophthalmology. Previously, he was the Dean of the Southern California College of Optometry at Marshall B. Ketchum University.

Dr. Jasper currently owns and operates Advanced Eyecare Specialists, a group optometry practice in West Palm Beach, Fla. She is a Benedict Professor in practice management at Houston College of Optometry and a community leader. Dr. Jasper is a fellow of the American Academy of Optometry (AAO) and past president of the Florida Optometric Association.

Eyenovia is developing a pipeline of micro-dose therapeutics utilizing its patented piezo-print delivery technology. Its pipeline is currently focused on the late-stage development of micro-dosed medications for presbyopia, myopia progression and mydriasis.